Dr Mila Felder Explains the Benefits of a Well-Being Council in Oncology Practices
April 11th 2024Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, shares the importance of incorporating a culture of well-being within oncology practices.
Dr Robert Sidbury on Implementing Value-Based Care Initiatives in a Pediatric Dermatology Practice
April 9th 2024Robert Sidbury, MD, MPH, FAAD, division head of dermatology at Seattle Children's Hospital and professor of pediatrics at the University of Washington School of Medicine, discusses implementing value-based care initiatives in a pediatric dermatology practice.
Dr Mila Felder Discusses How Peer Support Programs Can Help Alleviate Drug Shortage Distress
April 8th 2024Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, shares insights on how peer support groups can help manage psychological and emotional distress amid a national drug shortage.
Will Shapiro Discusses Ethical Challenges Across Various Artificial Intelligence Models in Oncology
April 5th 2024Will Shapiro, vice president of data science at Flatiron Health, explains the different ethical challenges associated with various forms of artificial intelligence models used in oncology care.
Dr Joseph Zabinski Discusses Using Artificial Intelligence to Identify Patients With GPP
April 4th 2024Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, discusses ways that AI is being integrated into personalized medicine for patients with generalized pustular psoriasis (GPP).
Dr Raj Chovatiya Explains Oral JAK Inhibitor Monitoring Protocols for AD Treatment
April 1st 2024Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University of Medicine and Science, described monitoring protocols for clinicians when using oral Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).
Dr Jeff Stark: Bimekizumab Shows Long-Term Efficacy When Used to Treat Patients With HS
April 1st 2024Despite the positive week 48 results when used to treat moderate to severe hidradenitis suppurativa (HS), Jeff Stark, MD, of Union Chimique Belge, noted that bimekizumab is still considered an investigational therapy for HS treatment as it has not yet received an FDA approval.
FDA Approves Ravulizumab-cwvz for Rare Autoimmune Disease
March 28th 2024Ravulizumab-cwvz (Ultomiris) received a label expansion by the FDA for the treatment of adult neuromyelitis optica spectrum disorder in patients with anti–aquaporin-4 antibodies after trials results showed it could prevent relapses.
Dr Raj Chovatiya Provides Evidence Supporting Oral JAK Inhibitor Use to Treat AD
March 24th 2024Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University of Medicine and Science, provided current clinical evidence supporting the use of oral Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).
JNJ-2113 Shows Promising Response Rates Compared With Competitor Oral Therapies for Psoriasis
March 19th 2024Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh, reports promising response rates and a good safety profile with JNJ-2113 in patients with moderate to severe plaque psoriasis.